Published in Nat Med on August 24, 2003
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med (2005) 4.28
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med (2004) 3.57
Oral tolerance. Immunol Rev (2005) 3.48
Recent advances in coeliac disease. Gut (2006) 3.20
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Oral tolerance. Immunol Rev (2011) 3.03
Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest (2008) 2.82
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med (2008) 2.28
Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2007) 2.10
Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity (2008) 2.09
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A (2008) 1.83
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74
Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A (2004) 1.69
The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes (2010) 1.68
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes (2008) 1.63
Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A (2012) 1.60
Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol (2011) 1.57
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes (2011) 1.52
CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci U S A (2011) 1.47
Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med (2010) 1.41
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD Mice. ISRN Endocrinol (2013) 1.39
Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood (2005) 1.39
Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol (2010) 1.38
Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3. Proc Natl Acad Sci U S A (2004) 1.38
Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J Clin Invest (2009) 1.37
Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Immunology (2007) 1.35
Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A (2007) 1.35
Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci U S A (2004) 1.32
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes (2008) 1.25
Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25
Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLoS One (2013) 1.21
Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One (2009) 1.20
Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J Immunol (2008) 1.19
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes (2009) 1.18
Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med (2010) 1.17
A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano (2014) 1.16
Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest (2005) 1.14
The role of the LAT-PLC-gamma1 interaction in T regulatory cell function. J Immunol (2010) 1.14
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J Immunol (2008) 1.11
Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes (2014) 1.11
Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes (2008) 1.10
Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev (2006) 1.09
Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus (2009) 1.08
Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol (2010) 1.06
Immunosuppressive effects of streptozotocin-induced diabetes result in absolute lymphopenia and a relative increase of T regulatory cells. Diabetes (2011) 1.05
Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood (2009) 1.03
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant (2011) 1.02
Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol (2009) 1.02
Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes (2012) 1.02
Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc Natl Acad Sci U S A (2007) 1.02
B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 1.00
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Regulatory T cells, a potent immunoregulatory target for CAM researchers: modulating tumor immunity, autoimmunity and alloreactive immunity (III). Evid Based Complement Alternat Med (2006) 0.98
Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T cells. Front Immunol (2011) 0.96
An early age-related increase in the frequency of CD4+ Foxp3+ cells in BDC2.5NOD mice. Immunology (2007) 0.96
Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis. Results Probl Cell Differ (2010) 0.96
Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol (2012) 0.95
MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol Ther (2013) 0.95
Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice. J Exp Med (2012) 0.95
Immune intervention in type 1 diabetes. Semin Immunol (2011) 0.94
In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Mol Ther (2011) 0.94
New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci (2008) 0.93
Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med (2009) 0.93
AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther (2008) 0.93
Minimally activated CD8 autoreactive T cells specific for IRBP express a high level of Foxp3 and are functionally suppressive. Invest Ophthalmol Vis Sci (2007) 0.93
T cells in the control of organ-specific autoimmunity. J Clin Invest (2015) 0.93
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med (2012) 0.92
Microbe-dendritic cell dialog controls regulatory T-cell fate. Immunol Rev (2010) 0.92
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J Clin Invest (2008) 0.91
Prevention of allograft rejection by amplification of Foxp3(+)CD4(+)CD25(+) regulatory T cells. Transl Res (2008) 0.91
Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-β/Smad3 signaling. PLoS One (2014) 0.91
Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol (2009) 0.90
Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target. PLoS One (2009) 0.90
T regulatory cells and transplantation tolerance. Transplant Rev (Orlando) (2010) 0.90
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife (2016) 0.89
The role of TNF-α in mice with type 1- and 2- diabetes. PLoS One (2012) 0.87
Boosting regulatory T cell function by CD4 stimulation enters the clinic. Front Immunol (2012) 0.87
Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells. Curr Opin Organ Transplant (2009) 0.87
T cell receptors are structures capable of initiating signaling in the absence of large conformational rearrangements. J Biol Chem (2012) 0.87
Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol (2014) 0.86
Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Am J Ther (2005) 0.86
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13
Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes (2005) 2.10
CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes (2008) 2.04
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes (2007) 1.98
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73
Murine pancreatic islet isolation. J Vis Exp (2007) 1.68
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67
A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63
Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61
Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55
IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54
The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45
Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells. Diabetes (2005) 1.44
Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One (2010) 1.43
Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol (2013) 1.42
Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39
Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood (2009) 1.37
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci U S A (2004) 1.32
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29
Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp (2007) 1.28
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28
Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27
The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med (2011) 1.26
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol (2002) 1.26
When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol (2002) 1.25
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25
Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol (2003) 1.25